NCT00283114View on ClinicalTrials.gov

A Safety Study of Lintuzumab in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome

PHASE1CompletedINTERVENTIONAL
Enrollment

82

Participants

Timeline

Start Date

November 30, 2005

Primary Completion Date

January 31, 2010

Study Completion Date

January 31, 2010

Conditions
Acute Myeloid LeukemiaMyelodysplastic SyndromeMyeloproliferative DisordersChronic Myelomonocytic Leukemia
Interventions
DRUG

lintuzumab

1.5 - 8 mg/kg IV (in the vein) on Days 1, 8, 15, 22 and 29 of Cycle 1; 1.5 - 8 mg/kg IV (in the vein) every other week for all subsequent cycles

Trial Locations (9)

10011

St. Vincent's Comprehensive Cancer Center, New York

10021

Memorial Sloan Kettering Cancer Center, New York

Weill Medical College of Cornell University, New York

29605

Cancer Center of the Carolinas, Greenville

46107

Indiana Oncology-Hematology Consultants, Indianapolis

62526

Cancer Care Specialists of Central Illinois, Decatur

76508

Scott & White Memorial Hospital, Temple

80218

Rocky Mountain Cancer Center, Denver

01605

University of Massachusetts Medical Center, Worcester

All Listed Sponsors
lead

Seagen Inc.

INDUSTRY

NCT00283114 - A Safety Study of Lintuzumab in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome | Biotech Hunter | Biotech Hunter